In subsequent clinical trials with magrolimab (also an IgG4‐based CD47 antibody), the major yet manageable side effects in various cancer types were anaemia and infusion‐related reactions that did not lead to an MTD.16, 17, 18. Here, CD47 is linked to anemia.